KelSie Biotech, a Boulder, CO-based creator of bioavailability delivery methods for active pharmaceutical ingredients, closed the first tranche of $5m in Series A funding.
The round was led by Salveo Capital, with participation from Arcadian Capital and other investors.
The company intends to use the funds for its scientific research and market expansion.
Led by Cameron Keluche, KelSie Biotech creates high bioavailability delivery methods for active pharmaceutical ingredients in the medical, nutraceutical and CBD/cannabis fields. The company licenses its patented and proprietary technologies which are based on novel particle morphology science and include dry-inhaled powder and true sublingual delivery systems. The dry-inhaled powder technology completed Phase I Clinical Trials for delivery of a stable measles vaccine.